Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biotechnology company developing nucleic acid therapies for rare neuromuscular diseases using its proprietary FORCE™ muscle-targeted delivery platform, with lead programs for Duchenne muscular dystrophy and myotonic dystrophy type 1 targeting commercial launch in 2027.
- Company typePublic
- Founded2017
- HeadquartersCambridge, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dyne Therapeutics does
Dyne Therapeutics is a clinical-stage biotechnology company developing nucleic acid therapies for genetically driven rare neuromuscular diseases. The company's core technology is the proprietary FORCE™ (Fab conjugated Oligonucleotide Repeatable Engine) platform, which conjugates therapeutic oligonucleotides to TfR1-binding antibody fragments to achieve targeted delivery to muscle tissue, addressing a long-standing barrier to muscle-directed nucleic acid therapeutics. Preclinical data also indicate the platform can cross the blood-brain barrier with approximately 75% MAPT RNA knockdown in nonhuman primates, signaling potential extension into CNS indications.
Dyne's pipeline includes two clinical-stage assets — zeleciment rostudirsen (DYNE-251) for Duchenne muscular dystrophy patients amenable to exon 51 skipping, which met its primary endpoint with 5.46% dystrophin expression and demonstrated functional improvement across all six endpoints at 24 months in the DELIVER trial; and zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1, now in the Phase 3 HARMONIA trial. Preclinical programs DYNE-302 (FSHD) and DYNE-401 (Pompe disease) extend the FORCE platform into additional indications. The company submitted a BLA for z-rostudirsen to the FDA in May 2026 with a target Q1 2027 U.S. launch.
Dyne is pre-commercial and derives no material product revenue. The company intends to commercialize via specialty pharmacy and 3PL distribution, field-based sales and medical affairs teams, and a patient services hub supporting HCP-administered infusion in rare disease centers. Pricing has not been disclosed, but the addressable populations are narrow (~1,600 U.S. patients for DMD exon 51, ~40,000 U.S. and ~55,000 EU patients for DM1). The business is funded by approximately $1.1 billion in cash at year-end 2025, supplemented by equity offerings and a Hercules Capital term loan facility of up to $400 million, providing runway into Q1 2028 ahead of first potential product revenue.
Dyne Therapeutics firmographics
Firmographics- Name
- Dyne Therapeutics
- Legal name
- Dyne Therapeutics, Inc.
- Website
- https://dyne-tx.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Dyne Therapeutics is a clinical-stage biotechnology company developing nucleic acid therapies for rare neuromuscular diseases using its proprietary FORCE™ muscle-targeted delivery platform, with lead programs for Duchenne muscular dystrophy and myotonic dystrophy type 1 targeting commercial launch in 2027.
- Ownership category
- akta.pro rank
Dyne Therapeutics industry classification
Industry- Product category
- Neuromuscular Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Dyne Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Dyne Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Revenue model
- Pharmaceutical Product Sales: Pre-commercial biotech company expecting to generate revenue from product sales following FDA approval. Lead products z-rostudirsen (DMD) and z-basivarsen (DM1) planned for potential launch in Q1 2027 and early 2028 respectively.
- No Current Revenue: Clinical-stage biotech with no commercial revenue as of FY2025. Reported net loss of $446.2 million with less than $1 million in revenue for FY2025.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Target market for approximately 1,600 DMD patients in the US amenable to exon 51 skipping |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Dyne Therapeutics product offering
Product offeringCore offering
Dyne Therapeutics is a clinical-stage biotechnology company developing nucleic acid therapeutics for serious, genetically driven neuromuscular diseases using its proprietary FORCE platform. Its pipeline targets Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease via antisense oligonucleotides conjugated to TfR1-binding antibody fragments for muscle-targeted delivery.
Product overview
Dyne Therapeutics is a clinical-stage biotechnology company developing nucleic acid therapies for rare genetically driven neuromuscular diseases using its proprietary FORCE platform. The company's portfolio includes two clinical-stage programs: zeleciment rostudirsen (DYNE-251) for Duchenne muscular dystrophy (DMD) and zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1). The FORCE platform enables targeted delivery of oligonucleotides to muscle tissue, overcoming previous delivery limitations. The company also has preclinical programs including DYNE-302 for facioscapulohumeral muscular dystrophy (FSHD) and DYNE-401 for Pompe disease.
Differentiator
Problem solved
Functional benefit
Products and services
- Zeleciment rostudirsen (DYNE-251) Antisense oligonucleotide therapy designed for patients with Duchenne muscular dystrophy amenable to exon 51 skipping. Delivered via the FORCE platform using TfR1-binding antibody fragments conjugated to therapeutic oligonucleotides. Has demonstrated 5.46% dystrophin expression at 6 months and functional improvement across all six endpoints in the DELIVER trial, with cardiopulmonary benefits through 24 months.
- Zeleciment basivarsen (DYNE-101) Therapeutic candidate for myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease. Leverages the FORCE platform for targeted muscle delivery. Has demonstrated early and sustained improvements in myotonia, muscle strength and function with favorable safety profile. Holds FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations.
- DYNE-302 Preclinical therapeutic program for facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle disease affecting face, shoulders, and upper arms with no approved disease-modifying treatments. Developed using the FORCE platform for muscle-targeted delivery.
- DYNE-401 Preclinical therapeutic program for Pompe disease, a rare lysosomal storage disorder affecting muscle tissue. Developed using the FORCE platform to address progressive muscle weakness due to glycogen accumulation and respiratory failure.
Quantifiable outcome
- 5.46% dystrophin expression at 6 months in DELIVER trial (primary endpoint met)
- +3 more outcomes
Companies that use Dyne Therapeutics
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Dyne Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Dyne Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Myotonic Dystrophy FoundationstrategicCollaboration on DM1 health insurance literacy research and patient advocacy initiatives. Foundation contributed to study design and interpretation of results. Joint poster presentation at AMCP 2026 Annual Conference.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Dyne Therapeutics competitors and assessment
Company assessmentEmerging players
- Edgewise Therapeutics: Clinical-stage biotech developing therapeutics for muscular dystrophies including DMD and Becker, sharing Dyne's muscle-disease focus and rare neuromuscular patient base.
- Solid Biosciences: Gene therapy company pursuing DMD with alternative modality to Dyne's ASO approach but same exon-skipping/genetic correction strategy and patient population.
- PepGen: Clinical-stage company developing conjugated oligonucleotide therapeutics for DMD and DM1, directly overlapping Dyne's lead indications and delivery-conjugate approach.
- Capricor Therapeutics: Cell therapy developer for DMD and other rare diseases, targeting the same patient and prescriber base as Dyne with a distinct but adjacent modality.
Direct peers
- PTC Therapeutics: Commercial-stage rare disease company with Translarna (ataluren) and other DMD/rare neuromuscular assets targeting the same patient and prescriber base as Dyne.
- Ionis Pharmaceuticals: Antisense oligonucleotide platform company and the originator of ASO chemistry used in many muscle/neuromuscular programs. Highly comparable core technology to Dyne's FORCE-conjugated ASO approach.
- Sarepta Therapeutics: The leading commercial-stage DMD therapeutic company, with approved exon-skipping ASOs (Exondys 51, Vyondys 53, Amondys 45) and gene therapy Elevidys. Directly comparable to Dyne given overlap in DMD exon-skipping modality and patient population.
Broad incumbents
- Alnylam Pharmaceuticals: Established RNAi therapeutics platform company with approved rare disease drugs and ongoing neuromuscular/hATTR programs. Comparable nucleic-acid delivery franchise and rare-disease commercial model.
- Ultragenyx Pharmaceutical: Commercial-stage rare disease biotech with approved neuromuscular and metabolic assets, sharing Dyne's commercial-build playbook for specialty-distributed orphan therapeutics.
- BioMarin Pharmaceutical: Established rare disease commercial-stage company with neuromuscular and gene therapy assets, providing comparable scale of rare-disease launch infrastructure and orphan commercialization expertise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Dyne Therapeutics social profiles
Digital presenceDyne Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dyne Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Dyne Therapeutics funding detail
Funding detailFunding overview
Funding rounds11 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dyne Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dyne Therapeutics
What does Dyne Therapeutics do?
Dyne Therapeutics is a clinical-stage biotechnology company developing nucleic acid therapeutics for serious, genetically driven neuromuscular diseases using its proprietary FORCE platform. Its pipeline targets Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease via antisense oligonucleotides conjugated to TfR1-binding antibody fragments for muscle-targeted delivery.
Is Dyne Therapeutics a public or private company?
Dyne Therapeutics is a public company. It is classified as public and is currently operating.
When was Dyne Therapeutics founded?
Dyne Therapeutics was founded in 2017. It employs 251 to 500 people.
Where is Dyne Therapeutics based?
Dyne Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Dyne Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are no Current Revenue.
Who are Dyne Therapeutics's main competitors?
Emerging players on record are Edgewise Therapeutics, Solid Biosciences, PepGen and Capricor Therapeutics. Direct peers are PTC Therapeutics, Ionis Pharmaceuticals and Sarepta Therapeutics. Broad incumbents are Alnylam Pharmaceuticals, Ultragenyx Pharmaceutical and BioMarin Pharmaceutical.
Does Dyne Therapeutics have an API?
No public API is recorded for Dyne Therapeutics.
What industry is Dyne Therapeutics in?
Dyne Therapeutics's product category is Neuromuscular Disease Therapeutics. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.